Meeting
2022 ASCO Annual Meeting
CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL).
Authors
Frederick L. Locke
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Frederick L. Locke , David Bernard Miklos , Michael Timothy Tees , Aojun Li , Anna Truppel-Hartmann , Ian W. Flinn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT05169489
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7580)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7580
Abstract #
TPS7580
Poster Bd #
231b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Efficacy and safety of CAR19/22 t-cell “cocktail” therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma.
First Author: Liang Huang
Poster
2023 ASCO Annual Meeting
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
First Author: Jianxiang Wang
Poster
2022 ASCO Annual Meeting
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Don A. Stevens
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe